Invex Therapeutics Ltd (ASX: IXC) Share Price and News

Mr McAuliffe is an experienced company director and entrepreneur who has had over twenty years' experience, mostly in the international biotechnology field. During that time, he was involved in capital raisings and in-licensing of technologies. He is a founder of several companies in Australia, France and the United Kingdom, many of which have become public companies. Mr McAuliffe is the President of the Dyslexia - Speld Foundation WA (Inc). Mr McAuliffe holds current directorships with held with 4DS Memory Limited

Ms Warren has over twenty years of corporate advisory, financial management and company secretarial experience. Ms Warren has coordinated and assisted in corporate transactions, including acquisitions, divestments and raising funds via private and public equity markets.

Mr Wheeler has more than 30 years of Senior Executive Management, Directorships, and Corporate Advisory experience. He is a foundation Director and Partner of Pathways Corporate a boutique Corporate Advisory firm that undertakes assignments on behalf of family offices, private clients, and ASX listed companies. Current directorships: Non-Executive Chairman - OZZ Resources Ltd from May 2022, Avira Resources Ltd from September 2018, Yugo Metals Ltd from November 2024; Non-Executive Director - Ragnar Metals Ltd from December 2017, MOAB Ltd (previously Delecta Ltd) from June 2020, Cycliq Group Ltd from June 2021, Earth Energy Ltd (previously Cardle Resources Ltd) from October 2021. Former directorships held in last three years Executive Chairman: Health House International Limited resigned May 2023. Non-Executive Chairman - PVW Resources Limited resigned October 2024. Non-Executive Director - Athena Resources Limited resigned September 2022, Color TV Limited resigned September 2023, Tyranna Resources Limited resigned June 2024, Wellfully Ltd resigned June 2024, Protean Energy Ltd delisted

Dr Duthy has over 21 years of direct financial market and executive level/Board experience with ASX listed companies. He is a Director and Founder of Nemean Group, which provides corporate advisory and Investor Relations (IR) services in the Healthcare and Technology sectors. This included an IR/Corporate Development advisory role with Nova Eye Medical (ASX:EYE), during which time a $100 million all-cash sale of their Lasers & Ultrasound business to Lumibird Group was completed (2020) and two further IR advisory roles with Limeade (ASX:LME), which was acquired for $111 million in cash by WebMD Health Services and Pivotal Systems (ASX:PVS), which was acquired for $25 million by OmegaX (both in 2023). Prior to establishing Nemean Group in October 2018, Dr Duthy was the Global Head of Investor Relations & Corporate Development at Sirtex Medical Limited (ASX:SRX), which was sold to CDH Investments in September 2018 for $1.9 billion. Prior to Sirtex, Tom spent ten years as a sell-side Healthcare & Biotechnology analyst at Taylor Collison Limited, focused mainly on small cap companies. Dr Duthy is currently an IR Advisor to Mayne Pharma (ASX:MYX), which is progressing a $672 million takeover offer from Cosette Pharmaceuticals. Former directorships held in last three years: PharmAust Limited - resigned 9 May 2024, Neurotech International Limited - resigned 1 April 2025, Arovella Therapeutics Ltd - retired 1 July 2025.